Skip to main content
OpenTrials

Clinical trial discovery

Find Clinical Trials

Search studies by condition, treatment, location, eligibility, or trial identifier.

Showing 1–20 of 80 trials

Active filters

Clinical trials found

Published and searchable clinical trials

Searching for clinical trials...
Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

NCT02120352

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Bakersfield, California, United States
  • GSK Investigational Site Beverly Hills, California, United States
  • GSK Investigational Site Long Beach, California, United States
View all 50 locations
View Trial Details
Completed

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

NCT01910402

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Bakersfield, California, United States
  • GSK Investigational Site Beverly Hills, California, United States
  • GSK Investigational Site Washington D.C., District of Columbia, United States
View all 90 locations
View Trial Details
Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

NCT02831764

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Sacramento, California, United States
  • GSK Investigational Site San Francisco, California, United States
View all 105 locations
View Trial Details
Completed

Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

NCT00071760

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Jacksonville, Florida, United States
  • GSK Investigational Site Durham, North Carolina, United States
  • GSK Investigational Site Buenos Aires, Argentina
  • GSK Investigational Site Mexico City, Mexico
View all 15 locations
View Trial Details
Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

NCT02831673

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Washington D.C., District of Columbia, United States
  • GSK Investigational Site Ft. Pierce, Florida, United States
  • GSK Investigational Site Orlando, Florida, United States
View all 90 locations
View Trial Details
Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

NCT01231516

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Bakersfield, California, United States
View all 180 locations
View Trial Details
Completed

Dolutegravir Expanded Access Study

NCT01536873

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site San Francisco, California, United States
  • GSK Investigational Site Denver, Colorado, United States
  • GSK Investigational Site Fort Lauderdale, Florida, United States
View all 74 locations
View Trial Details
Completed

Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

NCT03045861

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Bakersfield, California, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Los Angeles, California, United States
View all 14 locations
View Trial Details
Completed

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

NCT01641809

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Bakersfield, California, United States
View all 48 locations
View Trial Details
Completed

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

NCT01384734

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site San Francisco, California, United States
  • GSK Investigational Site San Francisco, California, United States
  • GSK Investigational Site Washington D.C., District of Columbia, United States
  • GSK Investigational Site Coral Gables, Florida, United States
View all 54 locations
View Trial Details
Completed

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

NCT00951015

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Bakersfield, California, United States
  • GSK Investigational Site Long Beach, California, United States
  • GSK Investigational Site San Francisco, California, United States
View all 35 locations
View Trial Details